Anti-CD4-mediated selection of Treg in vitro - in vitro suppression does not predict in vivo capacity to prevent graft rejection.
about
Regulatory T cells in transplantationAlpha-1,2-mannosidase and hence N-glycosylation are required for regulatory T cell migration and allograft tolerance in mice.In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.Homing of regulatory T cells to human skin is important for the prevention of alloimmune-mediated pathology in an in vivo cellular therapy model.Tumor regulatory T cells potently abrogate antitumor immunity.T regulatory cells and the control of alloimmunity: from characterisation to clinical application.CD4+ regulatory T cells in solid organ transplantation.Immunologic unresponsiveness to alloantigen in vivo: a role for regulatory T cells.Epigenomics in hematopoietic transplantation: novel treatment strategies.Boosting regulatory T cell function by CD4 stimulation enters the clinic.Induction of transplantation tolerance through regulatory cells: from mice to men.Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells.Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance.A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway.Epigenetic approaches in stem cell transplantationPermanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells.Generation of highly effective and stable murine alloreactive Treg cells by combined anti-CD4 mAb, TGF-β, and RA treatment.
P2860
Q27011620-4C2655E2-21CE-43F6-9A60-90662F3E26D6Q33529115-384F5224-2619-44F7-BB67-4509206BED65Q33997187-190546B0-CFE4-48FA-80C3-42A08B354061Q34541853-59672710-69C4-4FC2-BDBE-0D6F8A8ABDA9Q37317190-971B795C-ED9C-4398-BB81-E32E1036D395Q37792312-D4017AB7-9020-4989-B1A3-02F31B3E6EEFQ37794623-197EA5FA-4D82-4930-9DBD-4388D1983D90Q37864694-56F545B9-5385-42E8-9673-B9D9201B3432Q37962599-62CD01FD-21BC-4EBD-8131-B198D91E5726Q38020477-E0311AD4-1588-4A18-86FE-18123E49F493Q38187170-4EABB707-8C04-4EA1-BFCB-093E4560929FQ38491611-2E96C243-4A96-4EBE-B363-252AC83EFB5BQ38515353-7EAD6985-A7B5-4B42-92F9-58725F081FB1Q39887068-5A468C0A-79DF-4382-BD91-295126C35CFAQ41856433-2526FE89-4F90-4861-A854-5F9987F71C29Q47617412-2583B79C-8F09-4F82-866A-26F79E135687Q47778027-9AB035E6-64AD-4816-A854-92BBF8438B60
P2860
Anti-CD4-mediated selection of Treg in vitro - in vitro suppression does not predict in vivo capacity to prevent graft rejection.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Anti-CD4-mediated selection of ...... ty to prevent graft rejection.
@en
type
label
Anti-CD4-mediated selection of ...... ty to prevent graft rejection.
@en
prefLabel
Anti-CD4-mediated selection of ...... ty to prevent graft rejection.
@en
P2093
P2860
P356
P1476
Anti-CD4-mediated selection of ...... ty to prevent graft rejection.
@en
P2093
Christine Appelt
Elaine Long
Inga Gebuhr
Joanna Wieckiewicz
Kathryn J Wood
Stephanie Chapman
Vanessa Oliveira
P2860
P304
P356
10.1002/EJI.200737562
P407
P577
2008-06-01T00:00:00Z